Therapeutic options in development for management of diabetes: pharmacologic agents and new technologies.

Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
Harold E Lebovitz

Abstract

To review new pharmacologic therapies and technologies relevant to the management of diabetes and its complications. New treatment options for diabetes, made available through research efforts during the past 2 decades, are discussed. Several new drugs and drug classes for the management of diabetes are under development, including the incretin mimetic agents (exenatide, dipeptidyl peptidase 4 inhibitors, and glucagon-like peptide 1 analogues), the amylin analogue pramlintide, the cannabinoid-1 receptor antagonist rimonabant, the mixed peroxisome proliferator-activated receptor agonists muraglitazar and tesaglitazar, the inhaled insulin preparation Exubera, and the insulin analogues (insulin glulisine and insulin detemir). New drugs and technologic advances being made available will help achieve the goals of treating patients with diabetes to all the appropriate metabolic targets. Many other agents that act on fundamental abnormalities such as energy imbalance, inflammation, and vascular biologic conditions are in very early stages of development but are likely to become available during the next 5 to 10 years.

References

Jul 5, 2003·The Annals of Pharmacotherapy·Erika L Kleppinger, Eva M Vivian
Oct 27, 2004·Diabetes Care·John B BuseUNKNOWN Exenatide-113 Clinical Study Group
Feb 11, 2005·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Orville G KoltermanAlain D Baron
Mar 23, 2005·Regulatory Peptides·Michael A Nauck, Juris J Meier
Apr 14, 2005·The Annals of Pharmacotherapy·Peggy Soule Odegard, Kam L Capoccia
May 14, 2005·Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [and] German Diabetes Association·R RatnerC Weyer
Jun 7, 2005·Expert Opinion on Pharmacotherapy·Satish K GargHeather Ulrich
Jun 7, 2005·Life Sciences·Mauro A M CaraiGian Luigi Gessa
Oct 22, 2005·JAMA : the Journal of the American Medical Association·Steven E NissenEric J Topol

❮ Previous
Next ❯

Citations

Apr 26, 2007·Angiogenesis·Carla CostaRaquel Soares
Jun 6, 2007·Current Diabetes Reports·William T Cefalu
Mar 31, 2007·International Journal of Clinical Practice·J Tibaldi, R E Rakel
Feb 19, 2008·Osteopathic Medicine and Primary Care·Michael Valitutto
Apr 7, 2011·Journal of Multidisciplinary Healthcare·Bridget R Levich
Jul 14, 2007·European Journal of Pharmacology·Sherin Y BoctorCharles P France
Feb 27, 2007·Diabetes Research and Clinical Practice·Franziska P BusseMichael Stumvoll
Sep 11, 2008·Clinical Cardiology·Andrew ZinnArthur Schwartzbard

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.